Targeting memory T-cells in Type 1 diabetes
2013-09-23
(Press-News.org) WA, Seattle (September 23, 2013) – Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby M.D., Ph.D. from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology.
Alefacept, an engineered fusion protein targeting a surface molecule, CD2, found on T-lymphocytes, was the first biologic therapy approved for moderate to severe plaque psoriasis. By binding CD2, alefacept inhibits co-stimulation and induces T-cell depletion. T-cell mediated destruction of insulin producing pancreatic beta cells is a central feature of Type 1 diabetes, but targeting of CD2 has not previously been evaluated in this disease. The T1DAL trial was designed to test whether alefacept would preserve pancreatic beta cell function in newly diagnosed patients.
The Phase II T1DAL study enrolled 49 new-onset type 1 diabetic subjects, ages 12 to 35, who were randomized into two groups: 33 to alefacept and 16 to placebo. Patients received two twelve week courses (separated by a 12 week pause) of either alefacept or placebo. Twelve months from the start of the study, patients underwent a mixed meal tolerance test to measure the C-peptide response (a measure of insulin production). The primary endpoint, a 2-hour C-peptide response, did not show statistically significant differences between treatment and placebo groups; however, a secondary endpoint, a 4-hour C-peptide response, was significantly higher at 12 months in the treatment group compared to the placebo group. Other secondary endpoints including insulin use and rate of hypoglycemic events were significantly lower at 12 months in the alefacept treated group.
Although the primary endpoint was not met, these encouraging results of key secondary endpoints suggest a disease-modifying effect of alefacept. Additional support for alefacept's therapeutic role comes from analysis of T-cell subtypes of treated patients that showed that effector T cells were primarily targeted while sparing protective regulatory T cells. Lead investigator Dr. Mark Rigby suggests, "The T1DAL study is the first to use an agent to specifically deplete the cells which attack the pancreas in type 1 diabetes, the memory and effector T cells. We also found that regulatory T cells are not depleted with this therapy, suggesting that immune re-education can take place."
Longer 24 month follow-up of the subjects in this study is in progress to evaluate the potential for durable efficacy of the alefacept treatment. "Unfortunately our study was not able to enroll the goal number of participants due to drug availability which prevented more definitive conclusions at this point," said Dr. Rigby. "We are eagerly awaiting additional data over the next year which will help us determine if targeting memory T cells will help those with Type 1 diabetes make insulin for extended periods."
INFORMATION:
About The Immune Tolerance Network
The Immune Tolerance Network (ITN) is a research consortium sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The ITN develops and conducts clinical and mechanistic studies of immune tolerance therapies designed to prevent disease-causing immune responses, without compromising the natural protective properties of the immune system. Visit http://www.immunetolerance.org for more information.
Contact:
Philip Bernstein, PhD
(240) 235 6132
ITNCommunications@immunetolerance.org
Immune Tolerance Network
Office of the Director
1201 Ninth Avenue
Seattle, WA 98101-2795
206-342-6901
END
ELSE PRESS RELEASES FROM THIS DATE:
2013-09-23
New York, NY and Stockholm, Sweden -- A team of researchers affiliated with Ludwig Cancer Research and the Karolinska Institutet in Sweden report in the current issue of Nature Methods a dramatically improved technique for analyzing the genes expressed within a single cell -- a capability of relevance to everything from basic research to future cancer diagnostics.
"There are cells in tumors and in healthy tissues that are not present in sufficient numbers to permit analysis using anything but single-cell methods," explains senior author, Rickard Sandberg, PhD. "This method ...
2013-09-23
CHICAGO --- A fear memory was reduced in people by exposing them to the memory over and over again while they slept. It's the first time that emotional memory has been manipulated in humans during sleep, report Northwestern Medicine® scientists.
The finding potentially offers a new way to enhance the typical daytime treatment of phobias through exposure therapy by adding a nighttime component. Exposure therapy is a common treatment for phobia and involves a gradual exposure to the feared object or situation until the fear is extinguished.
"It's a novel finding," ...
2013-09-23
Since the discovery of the Van Allen radiation belts in 1958, space scientists have believed these belts encircling the Earth consist of two doughnut-shaped rings of highly charged particles — an inner ring of high-energy electrons and energetic positive ions and an outer ring of high-energy electrons.
In February of this year, a team of scientists reported the surprising discovery of a previously unknown third radiation ring — a narrow one that briefly appeared between the inner and outer rings in September 2012 and persisted for a month.
In new research, UCLA ...
2013-09-23
LOS ANGELES — Molecular microbiologists at the University of Southern California (USC) have uncovered intricate regulatory mechanisms within the cell that could lead to novel therapeutics for the treatment of cancer and other diseases. Their findings, which have long-standing significance in the basic understanding of cell biology, appear in the journal Nature Cell Biology.
"Our research reveals a new regulatory mechanism that coordinates two distinct intracellular processes that are critical to cellular homeostasis and disease development," said Chengyu Liang, M.D., ...
2013-09-23
Scientists have moved closer to developing a universal flu vaccine after using the 2009 pandemic as a natural experiment to study why some people seem to resist severe illness.
Researchers at Imperial College London asked volunteers to donate blood samples just as the swine flu pandemic was getting underway and report any symptoms they experienced over the next two flu seasons.
They found that those who avoided severe illness had more CD8 T cells, a type of virus-killing immune cell, in their blood at the start of the pandemic.
They believe a vaccine that stimulates ...
2013-09-23
The results of the new study imply that it is hard to fool the brain by providing it with 'energyless' sweet flavours. Our pleasure in consuming sweet solutions is driven to a great extent by the amount of energy it provides: greater reward in the brain is attributed to sugars compared to artificial sweeteners.
Professor Ivan de Araujo, who led the study at Yale University School of Medicine USA, says:
"The consumption of high-calorie beverages is a major contributor to weight gain and obesity, even after the introduction of artificial sweeteners to the market. We believe ...
2013-09-23
A lot of energy is wasted when machines turn hot, unnecessarily heating up their environment. Some of this thermal energy could be harvested using thermoelectric materials; they create electric current when they are used to bridge hot and cold objects. At the Vienna University of Technology (TU Vienna), a new and considerably more efficient class of thermoelectric materials can now be produced. It is the material's very special crystal structure that does the trick, in connection with an astonishing new physical effect; in countless tiny cages within the crystal, cerium ...
2013-09-23
New research on the most commonly used anaesthetic drug could help to unravel a long-standing mystery about how it induces a pain-free, sleep-like state.
General anaesthetics are administered to tens of millions of people every year in hospitals, where they are used to sedate patients undergoing surgery. Despite this, scientists have yet to understand how the drug interacts with its targets in brain cells to achieve this effect.
Following years of research on propofol, which has become the most commonly used anaesthetic since it was introduced in the 1980s, researchers ...
2013-09-23
Researchers at Washington University School of Medicine in St. Louis and Imperial College London have identified the site where the widely used anesthetic drug propofol binds to receptors in the brain to sedate patients during surgery.
Until now, it hasn't been clear how propofol connects with brain cells to induce anesthesia. The researchers believe the findings, reported online in the journal Nature Chemical Biology, eventually will lead to the development of more effective anesthetics with fewer side effects.
"For many years, the mechanisms by which anesthetics act ...
2013-09-23
Chronic aggressive behaviour exhibited by some boys from disadvantaged families may be due to epigenetic changes during pregnancy and early childhood. This is highlighted by two studies conducted by a team led by Richard E. Tremblay, professor emeritus at the University of Montreal and Moshe Szyf, professor at McGill University, published in the journal PLOS ONE. The first author of the two papers, Nadine Provençal, was jointly supervised by professors Szyf and Tremblay.
Epigenetic changes possibly related to the prenatal environment
In the first study, published in ...
LAST 30 PRESS RELEASES:
[Press-News.org] Targeting memory T-cells in Type 1 diabetes
